375856-62-5Relevant academic research and scientific papers
Method for preventing dyskinesias
-
, (2008/06/13)
Dyskinesias in humans are prevented by administering a therapeutically effective dose of a NR1A/2B site-selective NMDA receptor antagonist compound to a human.
Discovery of (R)-1-[2-hydroxy-3-(4-hydroxy-phenyl)-propyl]-4-(4-methyl-benzyl)-piperidin- 4-ol: A novel NR1/2B subtype selective NMDA receptor antagonist
Pinard, Emmanuel,Alanine, Alexander,Bourson, Anne,Buettelmann, Bernd,Gill, Ramanjit,Heitz, Marie-Paule,Jaeschke, Georg,Mutel, Vincent,Trube, Gerhard,Wyler, Rene
, p. 2173 - 2176 (2007/10/03)
Starting from Ro-25-6981 as a lead compound, highly potent and selective NR1/2B subtype selective NMDA receptor antagonists, with low activity at α1 adrenergic receptors were developed.
Phenylalkanolamine derivatives as antagonists of the NMDA receptor
-
, (2008/06/13)
Compounds of the formula ψψ ψ wherein ψ Ris hydrogen, hydroxy, or aryl lower alkyloxy; Xis hydrogen; Yis hydroxy or hydrogen; ψ or both X and Y taken together are oxygen; ψ Zis aryl lower alkyl; and mis an integer from 1 to 4 ψ or a diastereomer or an enantiomer thereof, except, the R,R diastereomer of formula I, wherein X is hydrogen, Y is hydroxy, R is benzyloxy, Z is benzyl, and m is 1, or pharmaceutically acceptable salts thereof, reduce adverse effects of toxic injury to central neurons and thus are useful in the treatment of ischemia, stroke, hypoxia and are NMDA receptor antagonists.ψ
